510(k) K250925

ADVIA Centaur Cytokeratin Fragment 21-1 by Fujirebio Diagnostics,Inc. — Product Code OVK

K250925 is an FDA 510(k) premarket notification submitted by Fujirebio Diagnostics,Inc. for the device "ADVIA Centaur Cytokeratin Fragment 21-1". The FDA issued a decision of Substantially Equivalent on Dec 16, 2025. The device falls under product code OVK (Cytokeratin Fragments 21-1 Eia Kit), a Class II device regulated under 21 CFR 866.6010. Fujirebio Diagnostics,Inc. has 44 other 510(k) clearances on record.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Dec 16, 2025
Date Received
Mar 27, 2025
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
Cytokeratin Fragments 21-1 Eia Kit
Device Class
Class II
Regulation Number
866.6010
Review Panel
IM
Submission Type
510(k)

The CYFRA 21-1 EIA kit is intended for the quantitative determination of soluble cytokeratin 19 fragments in human serum. The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in lung cancer patients. Serial testing for patient CYFRA 21-1 assay values should be used in conjunction with other clinical methods used for monitoring lung cancer.

Need the full FDA record for Fujirebio Diagnostics,Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K250925. Report a data issue: hello@regdatalab.com.